Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme.
暂无分享,去创建一个
S. Travis | M. Ferrante | G. Van Assche | W. Reinisch | P. Lakatos | R. Panaccione | J. Panés | C. J. van der Woude | J. Colombel | Z. Zelinková | A. Sturm | E. Newnham | K. Karmiris | J. Siffledeen | P. Lakatos | Z. Zelinkova
[1] J. Macdonald,et al. Methotrexate for maintenance of remission in Crohn's disease. , 2014, The Cochrane database of systematic reviews.
[2] G. Kaplan,et al. Budesonide for maintenance of remission in Crohn's disease. , 2014, The Cochrane database of systematic reviews.
[3] B. Feagan,et al. Methotrexate for induction of remission in refractory Crohn's disease. , 2014, The Cochrane database of systematic reviews.
[4] E. Purssell. Feverish illness in children Assessment and initial management in children younger than 5 years , 2013 .
[5] J. Macdonald,et al. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. , 2013, The Cochrane database of systematic reviews.
[6] B. Feagan,et al. Methotrexate for induction of remission in refractory Crohn's disease. , 2012, The Cochrane database of systematic reviews.
[7] S. Schreiber. Certolizumab pegol for the treatment of Crohn’s disease , 2011, Therapeutic advances in gastroenterology.
[8] R. Gearry,et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease , 2011, Inflammatory bowel diseases.
[9] J. Gisbert,et al. Early Use of Azathioprine Has a Steroid Sparing Effect on Recently Diagnosed Crohn's Disease Patients , 2011 .
[10] S. Fine. Adalimumab for the treatment of fistulas in patients with Crohn's disease. , 2011, Inflammatory bowel diseases.
[11] C. Glasmacher,et al. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. , 2011, Gastroenterology.
[12] U. Kopylov,et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab , 2011, Alimentary pharmacology & therapeutics.
[13] J. West,et al. Risk of Cancer in Inflammatory Bowel Disease Treated With Azathioprine: A UK Population-Based Case–Control Study , 2010, The American Journal of Gastroenterology.
[14] F. Carrat,et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy , 2010, Gut.
[15] W. Petritsch,et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial , 2010, Gut.
[16] P. Rutgeerts,et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.
[17] C. Porter,et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[18] H. Tilg,et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. , 2010, Journal of Crohn's & colitis.
[19] C. O'Morain,et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.
[20] P. Rutgeerts,et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. , 2010, Gastroenterology.
[21] P. Skolnik,et al. A Practical Guide to Vaccinating the Inflammatory Bowel Disease Patient , 2010, The American Journal of Gastroenterology.
[22] P. Rutgeerts,et al. The efficacy and safety of a third anti‐TNF monoclonal antibody in Crohn’s disease after failure of two other anti‐TNF antibodies , 2010, Alimentary pharmacology & therapeutics.
[23] Laurent Beaugerie,et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. , 2006, Journal of Crohn's & colitis.
[24] M. Picco,et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease , 2010 .
[25] P. Rutgeerts,et al. Immunosuppression-associated lymphoma in IBD , 2009, The Lancet.
[26] F. Carrat,et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study , 2009, The Lancet.
[27] P. Rutgeerts,et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.
[28] G. Kaplan,et al. Systematic review: the short‐term and long‐term efficacy of adalimumab following discontinuation of infliximab , 2009, Alimentary pharmacology & therapeutics.
[29] A. Cheifetz,et al. Interventions for prevention of post-operative recurrence of Crohn's disease. , 2009, The Cochrane database of systematic reviews.
[30] P. Rutgeerts,et al. Mucosal healing predicts long‐term outcome of maintenance therapy with infliximab in Crohn's disease , 2009, Inflammatory bowel diseases.
[31] B. Sands,et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[32] P. Rutgeerts,et al. Corticosteroids but not infliximab increase short‐term postoperative infectious complications in patients with ulcerative colitis , 2009, Inflammatory bowel diseases.
[33] M. Vos,et al. 961 Infliximab Discontinuation in Crohn's Disease Patients in Stable Remission On Combined Therapy with Immunosuppressors: A Prospective Ongoing Cohort Study , 2009 .
[34] Steven J Brown,et al. W1114 Methotrexate in Thiopurine Refractory Crohn's Disease - a Retrospective Cohort Study , 2009 .
[35] P. Rutgeerts,et al. Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial , 2009, The American Journal of Gastroenterology.
[36] A. Eriksson,et al. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease , 2009, Alimentary pharmacology & therapeutics.
[37] E. Benchimol,et al. Budesonide for maintenance of remission in Crohn's disease. , 2009, The Cochrane database of systematic reviews.
[38] S. Hanauer,et al. Management of Crohn's Disease in Adults , 2001, The American Journal of Gastroenterology.
[39] M. Picco. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study , 2009 .
[40] M. Cepoiu,et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. , 2009, The Cochrane database of systematic reviews.
[41] J. Macdonald,et al. Methotrexate for maintenance of remission in Crohn's disease. , 2009, The Cochrane database of systematic reviews.
[42] J. Mary,et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[43] H. Tilg,et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.
[44] K. Van Steen,et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.
[45] P. Rutgeerts,et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. , 2008, Gastroenterology.
[46] S. Saxena,et al. Preoperative Steroid Use and Risk of Postoperative Complications in Patients With Inflammatory Bowel Disease Undergoing Abdominal Surgery , 2008, The American Journal of Gastroenterology.
[47] R. D'Incà,et al. Can Calprotectin Predict Relapse Risk in Inflammatory Bowel Disease? , 2008, The American Journal of Gastroenterology.
[48] R. Panaccione,et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease , 2008, Gut.
[49] A. Cohen,et al. A Randomized Trial of Methotrexate in Combination With Infliximab for the Treatment of Crohn's Disease , 2008 .
[50] A. Staiano,et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[51] Jeffrey R Curtis,et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. , 2008, Arthritis and rheumatism.
[52] P. Rutgeerts,et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. , 2008, Gastroenterology.
[53] L. Peyrin-Biroulet,et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[54] A. Griffiths,et al. Traditional corticosteroids for induction of remission in Crohn's disease. , 2008, The Cochrane database of systematic reviews.
[55] W. Sandborn,et al. T1133 Efficacy and Tolerability of Certolizumab Pegol Are Sustained Over 18 Months: Data from PRECISE 2 and Its Extension Studies (PRECISE 3 and 4) , 2008 .
[56] P. Rutgeerts,et al. 946 Corticosteroids Pose An Increased Risk for Serious Infection: An Interim Safety Analysis of the ENCORE Registry , 2008 .
[57] S. McCartney,et al. W1235 Efficacy of Methotrexate in Crohns Disease Patients Previously On Thiopurine Therapy , 2008 .
[58] G. D'Haens,et al. 920 Adalimumab Maintains Long-Term Remission in Moderately to Severely Active Crohn's Disease After Infliximab Failure: 1-Year Follow-Up of Gain Trial , 2008 .
[59] A. Zinsmeister,et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. , 2008, Gastroenterology.
[60] W. S. Haubrich. Paneth of Paneth Cells , 2008 .
[61] M. Vos,et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.
[62] M. Färkkilä,et al. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings , 2008, Inflammatory bowel diseases.
[63] A. Michalsen,et al. Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices , 2008, The American Journal of Gastroenterology.
[64] Y. Yazdanpanah,et al. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis , 2007, Gut.
[65] G. D'Haens,et al. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial , 2008 .
[66] A. Griffiths,et al. Budesonide for induction of remission in Crohn's disease. , 2008, The Cochrane database of systematic reviews.
[67] A. Ford,et al. Mycophenolate mofetil therapy for refractory inflammatory bowel disease , 2007, Inflammatory bowel diseases.
[68] S. Targan,et al. Differences in the management of Crohn’s disease among experts and community providers, based on a national survey of sample case vignettes , 2007, Alimentary pharmacology & therapeutics.
[69] A. Griffiths,et al. Hepatosplenic T‐cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale? , 2007, Inflammatory bowel diseases.
[70] M. Vatn,et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. , 2007, Gastroenterology.
[71] P. Rutgeerts,et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. , 2007, Gastroenterology.
[72] J. Mate,et al. Thiopurine-Induced Liver Injury in Patients With Inflammatory Bowel Disease: A Systematic Review , 2007, The American Journal of Gastroenterology.
[73] M. De Vos,et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine , 2007, Gut.
[74] P. Rutgeerts,et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.
[75] M. Silverberg,et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[76] R. Modigliani,et al. A simple biological score for predicting low risk of short‐term relapse in Crohn's disease , 2006, Inflammatory bowel diseases.
[77] S. Dorn. Predictors of Crohn's disease. , 2006, Gastroenterology.
[78] W. Sandborn,et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[79] W. Tremaine,et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.
[80] Province,et al. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.
[81] A. Zinsmeister,et al. Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.
[82] C. Brensinger,et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine , 2005, Gut.
[83] R. Modigliani,et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. , 2005, Gastroenterology.
[84] W. Leslie,et al. Therapy Insight: osteoporosis in inflammatory bowel disease—advances and retreats , 2005, Nature Clinical Practice Gastroenterology &Hepatology.
[85] R. Caprilli,et al. Small Intestine Contrast Ultrasonography: An Alternative to Radiology in the Assessment of Small Bowel Disease , 2005, Inflammatory bowel diseases.
[86] B. Feagan,et al. Methotrexate for induction of remission in refractory Crohn's disease. , 2005, The Cochrane database of systematic reviews.
[87] P. Rutgeerts,et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. , 2004, Gastrointestinal endoscopy.
[88] A. Taschieri,et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. , 2004, Gastroenterology.
[89] R. Thisted,et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. , 2004, Gastroenterology.
[90] M. Dubinsky. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[91] D. Sanders,et al. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease , 2004, Gut.
[92] P. Rutgeerts,et al. Infliximab maintenance therapy for fistulizing Crohn's disease. , 2004, The New England journal of medicine.
[93] A. Griffiths,et al. Corticosteroids for maintenance of remission in Crohn's disease. , 2003, The Cochrane database of systematic reviews.
[94] S. Targan,et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. , 2003, Gastroenterology.
[95] W. Leslie,et al. AGA technical review on osteoporosis in gastrointestinal diseases. , 2003, Gastroenterology.
[96] J. Escher,et al. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease , 2003, Alimentary pharmacology & therapeutics.
[97] E. Louis,et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprine , 2003, Gut.
[98] J. Belaiche,et al. A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism , 2002 .
[99] F. Carbonnel,et al. Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.
[100] J. Belaiche,et al. Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With -308 TNF Gene Polymorphism , 2002, Scandinavian journal of gastroenterology.
[101] W. Sandborn. Rational dosing of azathioprine and 6-mercaptopurine , 2001, Gut.
[102] J. Markowitz,et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. , 2000, Gastroenterology.
[103] B. Bonaz,et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.
[104] O Bernell,et al. Risk factors for surgery and postoperative recurrence in Crohn's disease. , 2000, Annals of surgery.
[105] P. Rutgeerts,et al. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. , 1999, Gastrointestinal endoscopy.
[106] S. Targan,et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. , 1999, Gastroenterology.
[107] B. Feagan. Methotrexate treatment for Crohn's disease. , 1998, Inflammatory bowel diseases.
[108] P. Rutgeerts,et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. , 1997, Gastroenterology.
[109] M. Gerig,et al. A controlled double blind study of azathioprine in the management of Crohn's disease. , 1995, Gut.
[110] Loyd,et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. , 1995, The New England journal of medicine.
[111] D. Thompson,et al. Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. , 1995, Alimentary pharmacology & therapeutics.
[112] G. Greenberg,et al. Oral Budesonide for Active Crohn's Disease , 1994 .
[113] G. Greenberg,et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. , 1994, The New England journal of medicine.
[114] R. Modigliani,et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. , 1992, Gastroenterology.
[115] T. Bayless,et al. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. , 1991, Gastroenterology.
[116] P. Rutgeerts,et al. Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.
[117] R. Modigliani,et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. , 1990, Gastroenterology.
[118] A. Stuck,et al. Risk of infectious complications in patients taking glucocorticosteroids. , 1989, Reviews of infectious diseases.
[119] R. Weinshilboum,et al. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism , 1989, Clinical pharmacology and therapeutics.
[120] J Y Mary,et al. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). , 1989, Gut.
[121] R. Kozarek,et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. , 1989, Annals of internal medicine.
[122] K. Ewe,et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. , 1984, Gastroenterology.
[123] R. F. Harvey,et al. A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.
[124] R. Summers,et al. National Cooperative Crohn's Disease Study: results of drug treatment. , 1979, Gastroenterology.